CEBPE
Basic information
Region (hg38): 14:23117036-23120256
Links
Phenotypes
GenCC
Source:
- specific granule deficiency (Supportive), mode of inheritance: AR
- specific granule deficiency 1 (Strong), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Specific granule deficiency 1; Immunodeficiency 108 with autoinflammation | AR | Allergy/Immunology/Infectious | Individuals with Specific granule deficiency have severe immunocompromise, and antiinfectious prophylaxis and early and aggressive treatment of infections may be beneficial; Immunodeficiency108 with autoinflammation involves immunodeficiency, and antiinfectious prophylaxis and early and aggressive treatment of infections may be beneficia | Allergy/Immunology/Infectious | 10359588; 11313242; 31201888 |
ClinVar
This is a list of variants' phenotypes submitted to
- Specific_granule_deficiency (185 variants)
- Inborn_genetic_diseases (39 variants)
- not_provided (16 variants)
- CEBPE-related_disorder (11 variants)
- Specific_granule_deficiency_1 (9 variants)
- not_specified (4 variants)
- SPECIFIC_GRANULE_DEFICIENCY_1,_AUTOSOMAL_DOMINANT (1 variants)
- Pelger-Huet-like_anomaly_and_episodic_fever_with_abdominal_pain (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the CEBPE gene is commonly pathogenic or not. These statistics are base on transcript: NM_000001805.4. Only rare variants are included in the table.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Effect | PathogenicP | Likely pathogenicLP | VUSVUS | Likely benignLB | BenignB | Sum |
---|---|---|---|---|---|---|
synonymous | 73 | 78 | ||||
missense | 110 | 117 | ||||
nonsense | 4 | |||||
start loss | 0 | |||||
frameshift | 6 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
Total | 8 | 2 | 114 | 77 | 4 |
Highest pathogenic variant AF is 0.0000082137
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
CEBPE | protein_coding | protein_coding | ENST00000206513 | 2 | 2313 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.00708 | 0.927 | 125726 | 0 | 16 | 125742 | 0.0000636 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.233 | 180 | 189 | 0.952 | 0.0000131 | 1788 |
Missense in Polyphen | 84 | 87.333 | 0.96184 | 858 | ||
Synonymous | -0.705 | 90 | 81.9 | 1.10 | 0.00000577 | 609 |
Loss of Function | 1.59 | 5 | 10.6 | 0.473 | 8.07e-7 | 97 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.0000905 | 0.0000904 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.0000544 | 0.0000544 |
Finnish | 0.0000466 | 0.0000462 |
European (Non-Finnish) | 0.0000728 | 0.0000703 |
Middle Eastern | 0.0000544 | 0.0000544 |
South Asian | 0.0000988 | 0.0000980 |
Other | 0.000166 | 0.000163 |
dbNSFP
Source:
- Function
- FUNCTION: Transcriptional activator (PubMed:26019275). C/EBP are DNA-binding proteins that recognize two different motifs: the CCAAT homology common to many promoters and the enhanced core homology common to many enhancers. Required for the promyelocyte- myelocyte transition in myeloid differentiation (PubMed:10359588). {ECO:0000269|PubMed:10359588, ECO:0000269|PubMed:26019275}.;
- Disease
- DISEASE: Specific granule deficiency 1 (SGD1) [MIM:245480]: An autosomal recessive disorder characterized by recurrent pyogenic infections, defective neutrophil chemotaxis and bactericidal activity, and lack of neutrophil secondary granule proteins. Neutrophils of affected individuals lack lactoferrin and show abnormal nuclear segmentation, bilobed nuclei, low alkaline phosphatase, and increased number of neutrophil mitochondria and ribosomes. {ECO:0000269|PubMed:10359588, ECO:0000269|PubMed:11313242, ECO:0000269|PubMed:26019275}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Acute myeloid leukemia - Homo sapiens (human);Transcriptional misregulation in cancer - Homo sapiens (human)
(Consensus)
Recessive Scores
- pRec
- 0.213
Intolerance Scores
- loftool
- 0.507
- rvis_EVS
- -0.38
- rvis_percentile_EVS
- 27.69
Haploinsufficiency Scores
- pHI
- 0.483
- hipred
- N
- hipred_score
- 0.339
- ghis
- 0.520
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- E
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.944
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Cebpe
- Phenotype
- cellular phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); respiratory system phenotype; immune system phenotype; skeleton phenotype; digestive/alimentary phenotype; vision/eye phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); hematopoietic system phenotype;
Gene ontology
- Biological process
- phagocytosis;defense response;macrophage differentiation;granulocyte differentiation;cytokine biosynthetic process;defense response to bacterium;positive regulation of transcription by RNA polymerase II;cellular response to lipopolysaccharide
- Cellular component
- nucleus;nucleoplasm
- Molecular function
- RNA polymerase II proximal promoter sequence-specific DNA binding;DNA-binding transcription factor activity, RNA polymerase II-specific;DNA-binding transcription activator activity, RNA polymerase II-specific;protein binding;protein homodimerization activity;protein heterodimerization activity